Drug maker Lupin had settled all patent litigation over Solodyn tablets with Medicis Pharmaceutical Corp and signed a pact with the US-based firm for development of multiple therapeutic compounds. The pact would entail the Indian company receiving up to $38 million (over Rs 165 crore).
After the settlement agreement for the anti-biotic used for treating acne, Lupin is entitled to sell its generic versions of Solodyn in 45 mg, 90 mg, and 135 mg strengths under a licence from Medicis commencing November 2011, or earlier under certain conditions. The settlement also entitles Lupin to sell its generic versions of Solodyn in 65 mg and 115 mg strengths under a license from Medicis effective in February 2018. Further, Lupin can sell its generic versions of Solodyn in 55 mg, 80 mg and 105 mg strengths under a license from Medicis effective in February 2019, or earlier depending on certain conditions.
In another development, the company had also signed a research and development agreement with Medicis Pharmaceutical Corp. Under the terms of the agreement, Lupin will receive a $20 million (nearly Rs 90 crore) upfront payment from Medicis. The company will be primarily responsible for formulating certain novel therapeutic products for Medicis, utilising several of Lupin's formulation technologies. On the other hand, Medicis will have global exclusive rights (excluding India) for the products developed under the agreement. Lupin will be eligible for future research, development, regulatory and other milestones [payments] of up to $38 million, as well as a single digit royalty on sales by Medicis.crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
